Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects

Journal of Clinical Pharmacology

Volumn 55, Issue 9, 2015, Pages 1031-1041

  Meyers, Charles D ^a   Amer, Ahmed ^b   Majumdar, Tapan ^c   Chen, Jin ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NIBR   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

DGAT1 inhibitor; pharmacodynamics; pharmacokinetics; pradigastat; triglyceride

Indexed keywords

GLUCAGON LIKE PEPTIDE; GLUCOSE; INSULIN; PLACEBO; PRADIGASTAT; TRIACYLGLYCEROL; ACETIC ACID DERIVATIVE; AMINOPYRIDINE DERIVATIVE; DIACYLGLYCEROL ACYLTRANSFERASE;

ADULT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; PHARMACODYNAMICS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; ADOLESCENT; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; DOSE RESPONSE; HALF LIFE TIME; MIDDLE AGED; YOUNG ADULT;

ACETATES; ADOLESCENT; ADULT; AMINOPYRIDINES; AREA UNDER CURVE; DIACYLGLYCEROL O-ACYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; YOUNG ADULT;

EID: 84937739153     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.509     Document Type: Article

References (15)

1. Chen H, Farese R Jr,. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler Thromb Vasc Biol. 2005; 25 (3): 482-486.
2. Kawano Y, Cohen D., Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013; 48 (4): 434-441.
3. Meyers CD, Gaudet D, Trembley K, Amer A, Chen J, Aimin F., The DGAT1 inhibitor LCQ908 decreases triglyceride levels in patients with familial chylomicronemia syndrome. J Clin Lipidol. 2012; 6 (3): 266.
4. Zammit V, Buckett L, Turnbull A, Wure H, Proven A., Diacylglycerol acyltransferases: Potential roles as pharmacological targets. Pharmacol Ther. 2008; 118 (3): 295-302.
5. Chen H, Smith S, Ladha Z, et al., Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest. 2002; 109 (8): 1049-1055.
6. Buhman KK, Smith SJ, Stone SJ, et al., DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem. 2002; 277 (28): 25474-25479.
7. Cases S, Stone SJ, Zhou P, et al., Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem. 2001; 276 (42): 38870-38876.
8. Liu Q, Siloto R, Lehner R, Stone S, Weselake R,. Acyl-CoA: diacylglycerol acyltransferase: molecular biology, biochemistry and biotechnology. Prog Lipid Res. 2012; 51 (4): 350-377.
9. DeVita R, Pinto S., Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. J Med Chem. 2013; 56 (24): 9820-9825.
10. Lambert JE, Parks EJ., Postprandial metabolism of meal triglyceride in humans. Biochim Biophys Acta. 2012; 1821 (5): 721-726.
11. Smith S, Cases S, Jensen D, et al., Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet. 2000; 25 (1): 87-90.
12. Meyers CD, Serrano-Wu M, Amer A, et al., The DGAT1 inhibitor pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans. J Clin Lipidol. 2013; 7: 285.
13. FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 2005. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078932.pdf.
14. EMEA. Guideline on the investigation of bioequivalence. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf.
15. Knuth ND, Horowitz JF,. The elevation of ingested lipids within plasma chylomicrons is prolonged in men compared with women. J Nutr. 2006; 136 (6): 1498-1503.